Key result
Pimobendan was associated with a longer median survival time compared to standard treatment in cats with non-taurine responsive dilated cardiomyopathy.
Why the study?
Does pimobendan improve median survival time in cats with non-taurine responsive dilated cardiomyopathy?
Cohort (n=32)
Does pimobendan improve median survival time in cats with non-taurine responsive dilated cardiomyopathy?
Pimobendan significantly prolongs survival in cats with non-taurine responsive dilated cardiomyopathy compared to standard therapy alone.
Answers are grounded in this paper and cite their sources.
May support pimobendan in feline non-taurine responsive DCM; hypothesis-generating and requires prospective randomized confirmation.
This retrospective study was designed to assess the effect of pimobendan on the median survival time (MST) of cats with non-taurine responsive dilated cardiomyopathy (DCM). Thirty-two client-owned cats with a left ventricular internal dimension at end systole (LVIDs) >14 mm, a fractional shortening (FS) <28% and a lack of response to taurine therapy were included over a 9-year period (2001-2010). These cats were divided into pimobendan (n=16) and non-pimobendan (n=16) treatment groups. All cats received standard treatment with frusemide, taurine and benazepril or enalapril. Nine cats in the non-pimobendan group also received digoxin. The MST of the pimobendan group (49 days; range 1 to >502 days) was four times that of the non-pimobendan group (12 days; 1 to 244 days). The difference in survival between the two groups was statistically significant (P = 0.048). Hypothermia and FS <20% were associated with a poor prognosis. No adverse effects to pimobendan were noted.
No takes yet. Share an insight, caveat, or question.
Hambrook et al. (2012) conducted a cohort in non-taurine responsive dilated cardiomyopathy (DCM) (n=32). Pimobendan vs. Non-pimobendan (standard treatment) was evaluated on median survival time (MST) (p=0.048). Pimobendan was associated with a longer median survival time compared to standard treatment in cats with non-taurine responsive dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: